Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: Germany ; imaging ; NEW-YORK ; NUCLEAR-MEDICINE ; CONTRAST ; nuclear medicine ; radiology ; NUCLEAR ; USA
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: IN-VITRO ; AGENTS ; IN-VIVO ; PERFUSION ; THERAPY ; CT ; HEPATOCELLULAR-CARCINOMA ; liver ; TISSUE ; MRI ; CATHETER ; embolization ; X-RAY ; ARTERIOVENOUS-MALFORMATIONS ; MICROSPHERES ; ARTERY EMBOLIZATION ; ENDOVASCULAR EMBOLIZATION ; multimodal ; THERAPEUTIC EMBOLIZATION ; UTERINE FIBROID EMBOLIZATION
    Abstract: Objectives: Embolization therapy is gaining importance in the treatment of malignant lesions, and even more in benign lesions. Current embolization materials are not visible in imaging modalities. However, it is assumed that directly visible embolization material may provide several advantages over current embolization agents, ranging from particle shunt and reflux prevention to improved therapy control and follow-up assessment. X-ray-as well as magnetic resonance imaging (MRI)-visible embolization materials have been demonstrated in experiments. In this study, we present an embolization material with the property of being visible in more than one imaging modality, namely MRI and x-ray/computed tomography (CT). Characterization and testing of the substance in animal models was performed. Materials and Methods: To reduce the chance of adverse reactions and to facilitate clinical approval, materials have been applied that are similar to those that are approved and being used on a routine basis in diagnostic imaging. Therefore, x-ray-visible Iodine was combined with MRI-visible Iron (Fe3O4) in a macroparticle (diameter, 40-200 mu m). Its core, consisting of a copolymerized monomer MAOETIB (2-methacryloyloxyethyl [2,3,5-triiodobenzoate]), was coated with ultra-small paramagnetic iron oxide nanoparticles (150 nm). After in vitro testing, including signal to noise measurements in CT and MRI (n = 5), its ability to embolize tissue was tested in an established tumor embolization model in rabbits (n = 6). Digital subtraction angiography (DSA) (Integris, Philips), CT (Definition, Siemens Healthcare Section, Forchheim, Germany), and MRI (3 Tesla Magnetom Tim Trio MRI, Siemens Healthcare Section, Forchheim, Germany) were performed before, during, and after embolization. Imaging signal changes that could be attributed to embolization particles were assessed by visual inspection and rated on an ordinal scale by 3 radiologists, from 1 to 3. Histologic analysis of organs was performed. Results: Particles provided a sufficient image contrast on DSA, CT (signal to noise [SNR], 13 +/- 2.5), and MRI (SNR, 35 +/- 1) in in vitro scans. Successful embolization of renal tissue was confirmed by catheter angiography, revealing at least partial perfusion stop in all kidneys. Signal changes that were attributed to particles residing within the kidney were found in all cases in all the 3 imaging modalities. Localization distribution of particles corresponded well in all imaging modalities. Dynamic imaging during embolization provided real-time monitoring of the inflow of embolization particles within DSA, CT, and MRI. Histologic visualization of the residing particles as well as associated thrombosis in renal arteries could be performed. Visual assessment of the likelihood of embolization particle presence received full rating scores (153/153) after embolization. Conclusions: Multimodal-visible embolization particles have been developed, characterized, and tested in vivo in an animal model. Their implementation in clinical radiology may provide optimization of embolization procedures with regard to prevention of particle misplacement and direct intraprocedural visualization, at the same time improving follow-up examinations by utilizing the complementary characteristics of CT and MRI. Radiation dose savings can also be considered. All these advantages could contribute to future refinements and improvements in embolization therapy. Additionally, new approaches in embolization research may open up
    Type of Publication: Journal article published
    PubMed ID: 21263332
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CLASSIFICATION ; SYSTEM ; LESIONS ; ANGIOGRAPHY ; INTRAVASCULAR ULTRASOUND ; phantom ; ARTERY-DISEASE ; HEART-RATE ; 64-SLICE COMPUTED-TOMOGRAPHY
    Abstract: Abstract: Objective: To compare different CT acquisition techniques regarding for attenuation-based characterization of coronary atherosclerotic plaques using histopathology as the standard of reference. Materials and methods: In a post mortem study 17 human hearts were studied with dual-source CT (DSCT) and dual energy CT (DECT) mode on a DSCT as well as with 16-slice single-source CT (SSCT). At autopsy, atherosclerotic lesions were cut at 5 mu m sections. Histopathologic classification of the plaques according to the American Heart Association (AHA) criteria was performed by two pathologists. Attenuation values of all plaques were measured in DSCT, DECT and SSCT studies, respectively and classified based on attenuation according to modified AHA criteria. Results: 58 coronary plaques were identified at autopsy. Regardless of the CT technique only 52/58 plaques were found at CT (sensitivity = 89.6%). There was no significant difference between the mean attenuation values of different plaque types between DSCT, DECT, and SSCT: type IV: 11 HU/8 HU/19 HU; type Va: 44 HU/45 HU/52 HU; type Vb: 1088 HU/966 HU/1079 HU). The sensitivity for correct classification varied depending on the plaque type (type II = 0%, type III = 0%, type IV = 43%, type Va = 58%, Vb = 97%). Conclusion: Independent of the used acquisition technique, SSCT, DSCT and DECT show similar results for attenuation-based characterization of atherosclerotic coronary plaques.
    Type of Publication: Journal article published
    PubMed ID: 20810229
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: Germany ; COMMON ; CT ; DIAGNOSIS ; FOLLOW-UP ; imaging ; DISEASE ; MORTALITY ; NEW-YORK ; ACCURACY ; computed tomography ; NUCLEAR-MEDICINE ; PATIENT ; REPAIR ; EFFICIENT ; tomography ; COMPUTED-TOMOGRAPHY ; sensitivity ; specificity ; CT ANGIOGRAPHY ; ANGIOGRAPHY ; ARTERY ; nuclear medicine ; DISSECTION ; radiology ; HIGH-RESOLUTION ; THORACIC AORTA ; MORBIDITY ; PRINCIPLES ; NUCLEAR ; USA ; aneurysm ; Aorta ; MEDICINE ; NOV ; medical imaging ; ANEURYSMS ; German ; aortic dissection ; aortic disease ; INTRAMURAL HEMATOMA ; MULTIDETECTOR-ROW CT ; multisclice computed tomography (MSCT)
    Abstract: Aortic disease is associated with high morbidity and mortality and thus require an efficient and accurate diagnostic approach, especially in the acute setting. Multislice computed tomography (MSCT) with the option of high-resolution CT angiography (CTA) has emerged as the standard of reference in diagnosis and follow-up of patients with acquired aortic disease. Aortic dissection is the most common aortic emergency, but it remains undiscovered in up to 38% of cases. Sensitivity and specificity of MSCT in the assessment of aortic dissection are greater than 99%. The sensitivity of CT in the detection of inflammatory changes is 83%; its specificity is almost 100%; and its diagnostic accuracy is ca. 94%. This article outlines state-of-the-art principles in diagnostic CT imaging of acquired aortic disease
    Type of Publication: Journal article published
    PubMed ID: 17938873
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Abstract: Gadofosveset is a Gd-based protein-binding blood pool agent with increased relaxivities and blood half-life compared with conventional Gd-based contrast agents (GBCAs). No experience exists about the use of gadofosveset as an extracellular agent. In this report we present the first clinical experience with gadofosveset in enhancing intracranial tumors. Ten patients with different intracranial tumors were examined with a standard dose (0.03 mmol/kg) of gadofosveset compared with a standard dose (0.1 mmol/kg) of conventional GBCA. As a result of its significantly higher relaxivity, gadofosveset could, despite its low dose, achieve a sufficient contrast enhancement. The visual rating of the intensity of enhancement and the contrast to noise ratios were comparable to conventional agents. The detection and delineation of more complex lesions was rated equal. In one nonenhancing low grade astrocytoma an enhancing nodule became visible only 5 h after gadofosvesest injection. As shown in this initial report, contrast-enhanced intracranial tumor imaging is possible with the protein-binding blood pool agent gadofosveset. The agent gives a significant tumor contrast in early postcontrast imaging comparable with conventional agents. As a result of its unique longer lasting contrast, the use of gadofosveset might enable a new approach to imaging mild or nonenhancing tumors.
    Type of Publication: Journal article published
    PubMed ID: 19672603
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: ONCOLOGY
    Type of Publication: Meeting abstract published
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...